Candel Therapeutics (CADL) Gains from Sales and Divestitures (2023 - 2025)

Candel Therapeutics has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $330779.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $330779.0, down 82.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $330779.0 (down 82.92% YoY), and the FY2025 annual result was $330779.0, down 82.92% from the prior year.
• Gains from Sales and Divestitures came in at $330779.0 for Q4 2025 at Candel Therapeutics, roughly flat from $330779.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.9 million in Q4 2024 to a low of $306185.0 in Q4 2023.
• The 3-year median for Gains from Sales and Divestitures is $330779.0 (2025), against an average of $662924.4.
• Across the five-year window, Gains from Sales and Divestitures surged 532.45% in 2024 and sank 82.92% in 2025, its largest moves.
• Candel Therapeutics' Gains from Sales and Divestitures stood at $306185.0 in 2023, then soared by 532.45% to $1.9 million in 2024, then tumbled by 82.92% to $330779.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $330779.0 (Q4 2025), $330779.0 (Q3 2025), and $330779.0 (Q2 2025), per Business Quant data.